Bicara Therapeutics Inc.
BCAX
$14.81
$0.271.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -68.00M | -59.48M | -64.84M | -58.41M | -51.99M |
| Total Depreciation and Amortization | 56.00K | 55.00K | 42.00K | 30.50K | 19.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.32M | 5.86M | 17.64M | 16.80M | 15.96M |
| Change in Net Operating Assets | -14.13M | 807.00K | 1.10M | -4.26M | -9.62M |
| Cash from Operations | -74.75M | -52.76M | -46.06M | -45.85M | -45.63M |
| Capital Expenditure | -71.00K | -467.00K | -609.00K | -597.50K | -586.00K |
| Sale of Property, Plant, and Equipment | 62.00K | 62.00K | 62.00K | 31.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -9.00K | -405.00K | -547.00K | -566.50K | -586.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 335.01M | 335.01M | 1.55M | 850.00K | 149.00K |
| Repurchase of Common Stock | -975.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 194.70M | 234.52M | 253.43M | 272.35M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -596.00K | -298.00K | -- |
| Cash from Financing | 334.03M | 529.71M | 235.48M | 253.99M | 272.50M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 259.27M | 476.55M | 188.87M | 207.57M | 226.28M |